Myocardial deformation after radiotherapy: a layer-specific and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study).
Cardiac toxicity
Coronary arteries
Echocardiography
Multilayer strain
Radiation therapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
20 Aug 2020
20 Aug 2020
Historique:
received:
23
06
2020
accepted:
04
08
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Radiotherapy for breast cancer (BC) and its resulting cardiac exposure are associated with subclinical left ventricular dysfunction characterized by early decrease of global longitudinal strain (LS) measurement based on 2D speckle-tracking echocardiography. Recent software allows multi-layer and segmental analysis of strain, which may be of interest to quantify and locate the impact of cardiac exposure on myocardial function and potentially increase the early detection of radiation-induced cardiotoxicity. The aim of the study was to evaluate whether decrease in LS 6 months after radiotherapy is layer-specific and if it varies according to the left ventricular regional level and the coronary arterial territories. LS was measured at baseline before radiotherapy and 6 months post-radiotherapy. The LS was obtained for each myocardial layer (endocardial, mid-myocardial, epicardial), left ventricular regional level (basal, mid, apical) and coronary artery territory (left anterior descending artery (LAD), circumflex artery, right coronary artery). The study included 64 left-sided BC patients. Mean age was 58 years, mean doses to the heart, the left ventricle and the LAD were respectively 3.0, 6.7 and 16.4 Gy. The absolute decrease of LS was significant for the three layers (endocardial: - 20.0 ± 3.2% to - 18.8 ± 3.8%; mid-myocardial: - 16.0 ± 2.7% to - 15.0 ± 3.1%; epicardial: - 12.3 ± 2.5% to - 11.4 ± 2.8%, all p = 0.02), but only the relative decrease of LS in the endocardial layer was close to be significant (- 4.7%, p = 0.05). More precisely, the LS of the endocardial layer was significantly decreased for the most exposed parts of the left ventricle corresponding to the apical level (- 26.3 ± 6.0% vs. -24.2 ± 7.1%, p = 0.03) and LAD territory (- 22.8 ± 4.0% vs. -21.4 ± 4.8%, p = 0.03). Six months post-radiotherapy, LS decreased predominantly in the endocardial layer of the most exposed part of the left ventricle. For precise evaluation of radiotherapy-induced cardiotoxicity and early left ventricular dysfunction, the endocardial layer-based LS might be the most sensitive parameter. ClinicalTrials.gov: NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Radiotherapy for breast cancer (BC) and its resulting cardiac exposure are associated with subclinical left ventricular dysfunction characterized by early decrease of global longitudinal strain (LS) measurement based on 2D speckle-tracking echocardiography. Recent software allows multi-layer and segmental analysis of strain, which may be of interest to quantify and locate the impact of cardiac exposure on myocardial function and potentially increase the early detection of radiation-induced cardiotoxicity. The aim of the study was to evaluate whether decrease in LS 6 months after radiotherapy is layer-specific and if it varies according to the left ventricular regional level and the coronary arterial territories.
METHODS
METHODS
LS was measured at baseline before radiotherapy and 6 months post-radiotherapy. The LS was obtained for each myocardial layer (endocardial, mid-myocardial, epicardial), left ventricular regional level (basal, mid, apical) and coronary artery territory (left anterior descending artery (LAD), circumflex artery, right coronary artery).
RESULTS
RESULTS
The study included 64 left-sided BC patients. Mean age was 58 years, mean doses to the heart, the left ventricle and the LAD were respectively 3.0, 6.7 and 16.4 Gy. The absolute decrease of LS was significant for the three layers (endocardial: - 20.0 ± 3.2% to - 18.8 ± 3.8%; mid-myocardial: - 16.0 ± 2.7% to - 15.0 ± 3.1%; epicardial: - 12.3 ± 2.5% to - 11.4 ± 2.8%, all p = 0.02), but only the relative decrease of LS in the endocardial layer was close to be significant (- 4.7%, p = 0.05). More precisely, the LS of the endocardial layer was significantly decreased for the most exposed parts of the left ventricle corresponding to the apical level (- 26.3 ± 6.0% vs. -24.2 ± 7.1%, p = 0.03) and LAD territory (- 22.8 ± 4.0% vs. -21.4 ± 4.8%, p = 0.03).
CONCLUSION
CONCLUSIONS
Six months post-radiotherapy, LS decreased predominantly in the endocardial layer of the most exposed part of the left ventricle. For precise evaluation of radiotherapy-induced cardiotoxicity and early left ventricular dysfunction, the endocardial layer-based LS might be the most sensitive parameter.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT02605512 , Registered 6 November 2015 - Retrospectively registered.
Identifiants
pubmed: 32819449
doi: 10.1186/s13014-020-01635-y
pii: 10.1186/s13014-020-01635-y
pmc: PMC7439550
doi:
Banques de données
ClinicalTrials.gov
['NCT02605512']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
201Subventions
Organisme : Fédération Française de Cardiologie
ID : -
Organisme : Électricité de France
ID : -
Organisme : H2020 Euratom
ID : 755523
Références
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):182-190
pubmed: 28816145
J Am Soc Echocardiogr. 2015 Feb;28(2):183-93
pubmed: 25623220
Radiat Oncol. 2019 Nov 14;14(1):204
pubmed: 31727075
J Am Soc Echocardiogr. 2010 Jan;23(1):64-70
pubmed: 20122496
J Clin Oncol. 2007 Jul 20;25(21):3031-7
pubmed: 17634481
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656-65
pubmed: 20159360
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):836-44
pubmed: 26530752
Int J Cardiovasc Imaging. 2017 Apr;33(4):463-472
pubmed: 27873127
Radiat Oncol. 2016 Apr 07;11:54
pubmed: 27056179
J Clin Oncol. 2012 Feb 1;30(4):350-2
pubmed: 22203762
Int J Cardiol. 2017 Sep 15;243:204-208
pubmed: 28587740
JACC Cardiovasc Imaging. 2013 May;6(5):535-44
pubmed: 23582354
Strahlenther Onkol. 2019 Jan;195(1):1-12
pubmed: 30310926
Eur J Echocardiogr. 2009 Mar;10(2):303-8
pubmed: 18801725
Radiat Oncol. 2019 Feb 7;14(1):29
pubmed: 30732640
Radiat Oncol. 2019 Mar 7;14(1):40
pubmed: 30845947
Am J Physiol. 1999 Apr;276(4):H1305-12
pubmed: 10199856
Acta Oncol. 2016 Aug;55(8):959-63
pubmed: 27230730
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
Echocardiography. 2018 Sep;35(9):1300-1309
pubmed: 29756381
Arch Cardiovasc Dis. 2018 Apr;111(4):285-296
pubmed: 29422386
J Clin Oncol. 2012 Feb 1;30(4):380-6
pubmed: 22203772
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1444-51
pubmed: 20605341
Radiother Oncol. 2019 Mar;132:148-154
pubmed: 30414755
Am J Pathol. 1980 Mar;98(3):663-80
pubmed: 7361850
Heart Vessels. 2000;15(1):11-7
pubmed: 11001480
Semin Radiat Oncol. 2001 Jul;11(3):224-33
pubmed: 11447579
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93
pubmed: 25239940
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):182-90
pubmed: 24725701
Ultrasound Med Biol. 2019 Jan;45(1):98-107
pubmed: 30366608
Anticancer Res. 2019 Aug;39(8):4227-4236
pubmed: 31366510
Circ Cardiovasc Imaging. 2017 Mar;10(3):
pubmed: 28264868
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1172-8
pubmed: 23149005